CN1437594A - 用于治疗异常细胞生长的取代的双环衍生物 - Google Patents

用于治疗异常细胞生长的取代的双环衍生物 Download PDF

Info

Publication number
CN1437594A
CN1437594A CN01811470A CN01811470A CN1437594A CN 1437594 A CN1437594 A CN 1437594A CN 01811470 A CN01811470 A CN 01811470A CN 01811470 A CN01811470 A CN 01811470A CN 1437594 A CN1437594 A CN 1437594A
Authority
CN
China
Prior art keywords
methyl
yloxy
phenylamino
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01811470A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·卡瑟
S·K·巴塔查尔亚
J·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1437594A publication Critical patent/CN1437594A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CN01811470A 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物 Pending CN1437594A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
US60/213,136 2000-06-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2004100696071A Division CN1330640C (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CNA200810144110XA Division CN101348467A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Publications (1)

Publication Number Publication Date
CN1437594A true CN1437594A (zh) 2003-08-20

Family

ID=22793862

Family Applications (3)

Application Number Title Priority Date Filing Date
CN01811470A Pending CN1437594A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CNB2004100696071A Expired - Fee Related CN1330640C (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CNA200810144110XA Pending CN101348467A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004100696071A Expired - Fee Related CN1330640C (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CNA200810144110XA Pending CN101348467A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Country Status (42)

Country Link
US (2) US6890924B2 (enExample)
EP (1) EP1292591B1 (enExample)
JP (1) JP4044839B2 (enExample)
KR (1) KR100545537B1 (enExample)
CN (3) CN1437594A (enExample)
AP (1) AP2001002192A0 (enExample)
AR (1) AR032353A1 (enExample)
AT (1) ATE288431T1 (enExample)
AU (1) AU2001264159A1 (enExample)
BG (1) BG107269A (enExample)
BR (1) BR0111548A (enExample)
CA (1) CA2413424C (enExample)
CZ (1) CZ20023951A3 (enExample)
DE (1) DE60108754T2 (enExample)
DK (1) DK1292591T3 (enExample)
DZ (1) DZ3407A1 (enExample)
EA (1) EA005525B1 (enExample)
EC (1) ECSP024393A (enExample)
EE (1) EE200200710A (enExample)
ES (1) ES2236240T3 (enExample)
GE (1) GEP20063831B (enExample)
HR (1) HRP20021005A2 (enExample)
HU (1) HUP0301120A2 (enExample)
IL (1) IL152985A0 (enExample)
IS (1) IS6616A (enExample)
MA (1) MA26914A1 (enExample)
MX (1) MXPA02012870A (enExample)
MY (1) MY127181A (enExample)
NO (1) NO20026166L (enExample)
NZ (1) NZ522568A (enExample)
OA (1) OA12291A (enExample)
PA (1) PA8520301A1 (enExample)
PE (1) PE20020257A1 (enExample)
PL (1) PL359557A1 (enExample)
PT (1) PT1292591E (enExample)
SK (1) SK17102002A3 (enExample)
SV (1) SV2002000504A (enExample)
TN (1) TNSN01091A1 (enExample)
UA (1) UA73990C2 (enExample)
WO (1) WO2001098277A2 (enExample)
YU (1) YU95102A (enExample)
ZA (1) ZA200210231B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102872018A (zh) * 2012-10-23 2013-01-16 张健存 酪氨酸激酶不可逆抑制剂及其制备方法和用途
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
BR9914162A (pt) * 1998-10-01 2001-06-26 Astrazeneca Ab Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
TWI309647B (enExample) * 2001-02-21 2009-05-11 Mitsubishi Tanabe Pharma Corp
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
RU2004116345A (ru) * 2001-11-30 2005-03-27 Пфайзер Продактс Инк. (Us) Способы получения замещенных бициклических производных, полезных для лечения патологического роста клеток
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP4611745B2 (ja) 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
EP1575592A1 (en) * 2002-12-18 2005-09-21 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
KR20050118726A (ko) * 2003-04-09 2005-12-19 화이자 프로덕츠 인코포레이티드 Ｎ-((((피리딘일옥시)-페닐아미노)퀴나졸리닐)-알릴)아세트아마이드 유도체와 이와 관련된 화합물의 제조방법, 이제조방법의 중간체, 및 이 중간체의 제조방법
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
BRPI0412664A (pt) * 2003-07-15 2006-09-26 Ca Nat Research Council método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
EP1660090B1 (en) * 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
JP2007510708A (ja) * 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
EP1792898A1 (en) * 2004-09-01 2007-06-06 Mitsubishi Pharma Corporation Molecular chaperone function regulator
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
DK1933871T3 (da) 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
BRPI0715016A2 (pt) * 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
WO2009113560A1 (ja) 2008-03-12 2009-09-17 武田薬品工業株式会社 縮合複素環化合物
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
MX2016014143A (es) 2014-04-30 2017-02-15 Pfizer Derivados de diheterociclo enlazado a cicloalquilo.
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
ES3007082T3 (en) 2018-09-18 2025-03-19 Hoffmann La Roche Quinazoline derivatives as antitumor agents
TW202530231A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的可藥用鹽、其結晶形式及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
HK1039126B (en) 1998-10-08 2005-09-30 阿斯特拉曾尼卡有限公司 Quinazoline derivatives
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102872018A (zh) * 2012-10-23 2013-01-16 张健存 酪氨酸激酶不可逆抑制剂及其制备方法和用途
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
EP4501925A4 (en) * 2022-03-28 2025-08-27 Jiangsu Hengrui Pharmaceuticals Co Ltd NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF

Also Published As

Publication number Publication date
EP1292591B1 (en) 2005-02-02
DK1292591T3 (da) 2005-05-30
DZ3407A1 (enExample) 2001-12-27
IS6616A (is) 2002-11-14
KR100545537B1 (ko) 2006-01-25
WO2001098277A2 (en) 2001-12-27
IL152985A0 (en) 2003-06-24
AU2001264159A1 (en) 2002-01-02
WO2001098277A3 (en) 2002-06-13
GEP20063831B (en) 2006-05-25
ECSP024393A (es) 2003-02-06
JP2004501139A (ja) 2004-01-15
PL359557A1 (en) 2004-08-23
NO20026166D0 (no) 2002-12-20
YU95102A (sh) 2005-11-28
UA73990C2 (en) 2005-10-17
BR0111548A (pt) 2003-05-06
TNSN01091A1 (fr) 2005-11-10
HUP0301120A2 (hu) 2003-08-28
EA200201277A1 (ru) 2003-06-26
MA26914A1 (fr) 2004-12-20
EP1292591A2 (en) 2003-03-19
NO20026166L (no) 2002-12-20
SK17102002A3 (sk) 2004-04-06
MXPA02012870A (es) 2003-05-14
DE60108754D1 (de) 2005-03-10
EE200200710A (et) 2004-06-15
HK1069576A1 (en) 2005-05-27
PE20020257A1 (es) 2002-04-08
OA12291A (en) 2004-03-18
PA8520301A1 (es) 2003-06-30
NZ522568A (en) 2004-12-24
ATE288431T1 (de) 2005-02-15
KR20030016303A (ko) 2003-02-26
JP4044839B2 (ja) 2008-02-06
CN1576275A (zh) 2005-02-09
AP2001002192A0 (en) 2002-12-21
CN101348467A (zh) 2009-01-21
AR032353A1 (es) 2003-11-05
PT1292591E (pt) 2005-06-30
US20050159435A1 (en) 2005-07-21
BG107269A (bg) 2003-06-30
HRP20021005A2 (en) 2004-02-29
CN1330640C (zh) 2007-08-08
ZA200210231B (en) 2004-02-12
EA005525B1 (ru) 2005-04-28
CA2413424C (en) 2007-10-02
DE60108754T2 (de) 2005-06-23
US20020169165A1 (en) 2002-11-14
US7332493B2 (en) 2008-02-19
ES2236240T3 (es) 2005-07-16
MY127181A (en) 2006-11-30
US6890924B2 (en) 2005-05-10
CA2413424A1 (en) 2001-12-27
CZ20023951A3 (cs) 2004-01-14
SV2002000504A (es) 2002-10-24

Similar Documents

Publication Publication Date Title
CN1437594A (zh) 用于治疗异常细胞生长的取代的双环衍生物
CN1319966C (zh) 可用作抗增殖剂的新苯并咪唑衍生物
CN1134438C (zh) 二环杂芳族化合物、其制备方法以及用途
CN1182123C (zh) 用作抗癌剂的取代的二环衍生物
CN1602195A (zh) 用于治疗异常细胞生长的喹唑啉衍生物
US7585869B2 (en) Substituted heterocylces for the treatment of abnormal cell growth
US20050101618A1 (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
CN1094043A (zh) 喹唑啉衍生物
CN1886384A (zh) 喹唑酮化合物作为抗癌药剂
US20080194596A1 (en) Therapeutic Combination Including a Selective Erbb2 Inhibitor
CN1347416A (zh) 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂
CN1863794A (zh) 作为血管生成抑制剂的喹唑啉衍生物
CN1639149A (zh) 制备用于治疗异常细胞生长的取代的双环衍生物的方法
CN1863534A (zh) 作为vegf受体酪氨酸激酶抑制剂的喹唑啉衍生物
JP2006513179A (ja) 異常細胞増殖の治療のための４−アニリノキナゾリン誘導体
CN1852714A (zh) 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
HK1054747A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
HK1078571B (en) Novel benzoimidazole derivatives useful as antiproliferative agents
HK1071293A (en) Quinazoline derivatives for the treatment of abnormal cell growth
HK1069576B (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
HK1075042A (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
HK1082211A (en) 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
HK1050525A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
HK1050687A (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054747

Country of ref document: HK